中国实用外科杂志

• 指南(共识)解读 • 上一篇    下一篇

日本《大肠癌治疗指南(2024年版)》更新解读#br#

李    伟,所    剑   

  1. 吉林大学第一医院普通外科中心胃结直肠外科,吉林长春 130021
  • 出版日期:2025-04-01

  • Online:2025-04-01

摘要: 日本《大肠癌治疗指南(2024年版)》(以下简称指南)于2024年7月正式发布,在继承2022年版指南核心内容的基础上,针对内镜治疗、外科手术、药物治疗和放射线治疗等多个领域进行了必要的修订与优化。指南特别更新了大肠癌分期治疗策略,并针对微卫星高度不稳定性及BRAF基因突变大肠癌的新型治疗方法进行了调整,以更好地适应最新研究进展。在治疗策略方面,指南涵盖了早期大肠癌(0~Ⅲ期)和晚期大肠癌(Ⅳ期)治疗的最新证据,强调精准化和个体化治疗。此外,指南更新了直肠癌的全程新辅助治疗和非手术管理的适应证,同时引入了粒子放射线治疗作为难治性复发直肠癌的治疗选择。在Ⅳ期大肠癌的治疗方面,指南修订了血行转移的治疗策略,推荐在符合条件的情况下采用根治性切除,并纳入放射消融和立体定向放射治疗作为治疗选择。药物治疗部分更新了针对不可切除或复发性大肠癌的靶向治疗方案。此外,指南调整了错配修复功能缺陷和肿瘤突变负荷高大肠癌的免疫治疗适应证,推荐帕博利珠单抗作为主要治疗方案。放射线治疗部分新增了术前和术后化学放射治疗的比较,并优化了术前放疗的适应证,以降低局部复发风险。此外,针对复发性大肠癌,指南更新了局部治疗与全身治疗的结合策略,特别是在直肠癌局部复发、远处转移灶的管理方面提供了更细致的治疗建议。

关键词: 大肠癌, 治疗指南, 精准医疗, 个体化治疗, 靶向治疗, 免疫治疗, 放射治疗, 微卫星不稳定性

Abstract: Japanese Guidelines for Colorectal Cancer Treatment (2024 Edition) were officially released in July 2024. Building upon the core content of the 2022 edition, the new guidelines incorporate necessary revisions and optimizations across multiple areas, including endoscopic treatment, surgical procedures, pharmacotherapy, and radiotherapy. The guidelines notably update the staging and treatment strategies for colorectal cancer and adjust novel therapeutic approaches for colorectal cancer with high microsatellite instability and BRAF gene mutations to better reflect the latest research advancements. In terms of treatment strategy, the guidelines encompass the most recent recommendations for both early colorectal cancer (Stage 0-Ⅲ) and advanced colorectal cancer (Stage Ⅳ), emphasizing precision and individualized therapy. In addition, the guidelines have updated the indications for total neoadjuvant therapy and non-operative management in rectal cancer, and have introduced particle radiotherapy as a treatment option for refractory recurrent rectal cancer. Regarding the treatment of Stage Ⅳ colorectal cancer, the guidelines revise the treatment strategies for hematogenous metastases, recommending radical resection when feasible, and incorporating radiotherapy ablation and stereotactic body radiotherapy as treatment options. The pharmacotherapy section updates targeted therapy regimens for unresectable or recurrent colorectal cancer.  Furthermore, the guidelines adjust immunotherapy indications for colorectal cancer with mismatch repair deficiency and high tumor mutation burden, recommending pembrolizumab as the primary treatment option. In the radiotherapy section, a comparison between preoperative and postoperative chemoradiotherapy is introduced, and indications for preoperative radiotherapy are optimized to reduce the risk of local recurrence. Additionally, for recurrent colorectal cancer, the guidelines update strategies for combining local and systemic treatments, offering more detailed recommendations for managing local recurrence of rectal cancer and distant metastatic lesions. 

Key words: colorectal cancer, treatment guidelines, precision medicine, personalized treatment, targeted therapy, immunotherapy, radiation therapy, microsatellite instability